

Durvalumab

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.

The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

Rejected

General description

INN

Durvalumab

ATC codes

[L01FF03](#)

Medicine type

Biological agent

EML status history

Application rejected in 2023 ([TRS 1049](#)) for [Other specified malignant neoplasms of bronchus or lung](#)

Application rejected in 2025 ([TRS 1064](#)) for [Malignant neoplasm of intrahepatic bile ducts](#)

Application rejected in 2025 ([TRS 1064](#)) for [Malignant neoplasms of gallbladder](#)

Application rejected in 2025 ([TRS 1064](#)) for [Malignant neoplasms of biliary tract, distal bile duct](#)

Application rejected in 2025 ([TRS 1064](#)) for [Hepatocellular carcinoma of liver](#)

Application rejected in 2025 ([TRS 1064](#)) for [Malignant neoplasms of proximal biliary tract, cystic duct](#)

Therapeutic equivalent for

Wikipedia

[Durvalumab](#)

DrugBank

[Durvalumab](#)

Recommendations

Section

Immunomodulators

- Parenteral > General injections > IV: 50 mg per mL in 2.4 mL vial concentrate solution for infusion; 50 mg per mL in 10 mL vial concentrate solution for infusion

Indications

[Other specified malignant neoplasms of bronchus or lung](#) [Malignant neoplasm of intrahepatic bile ducts](#) [Malignant neoplasms of gallbladder](#) [Malignant neoplasms of biliary tract, distal bile duct](#) [Hepatocellular carcinoma of liver](#) [Malignant neoplasms of proximal biliary tract, cystic duct](#)